An interventional study of Gain framing email and Loss framing email in Influenza, Vaccination Coverage and Healthcare Worker, sponsored by Istituto Clinico Humanitas. Active, not recruiting at 17 sites in Italy. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Istituto Clinico Humanitas · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Influenza, Human with a site in Italy — 3 open to participants now, 4 under way, 2 of them phase 3. Influenza, Human · Italy.
Among the 52 studies in Influenza, Human with a site in Italy, this one has the largest planned enrollment of the 44 interventional ones that give a count, is the only one that started in 2026, is the only one with no phase, and was the 52nd registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →3 of the 52 studies in Influenza, Human with a site in Italy are open now. Recruiting first, the newest first:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Italy
Ages 18–70 · Healthy volunteers
AstraZeneca · Sites in Italy, United States, Argentina and 36 more countries
Ages 18+
UMC Utrecht · Sites in Italy, United States, Australia and 26 more countries
Ages 28 days+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 22 · Phase 3 16 · Phase 4 5
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 45,000 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 136 across the 44 interventional studies, 4,529 across the 7 observational. Of the 47 that completed or were terminated, 18 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 52 have an industry lead sponsor. The 10 most frequent:
Istituto Clinico Humanitas is the lead sponsor of 280 studies on the registry; 70 are open to participants now.
Istituto Clinico Humanitas has 1 study filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
2 of the studies in Influenza, Human with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07941427Istituto Clinico HumanitasIncreasing Flu Vaccination Through Evidence-Based Nudges | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Influenza, Human with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to find out whether changing the wording and content of workplace emails can encourage more healthcare and non-healthcare staff to get a seasonal flu vaccine. The main question is whether emails that highlight the benefits of vaccination, the possible consequences of not getting vaccinated, or vaccination rates among colleagues are more effective than standard information emails.
The study will take place during the 2026-2027 flu vaccination campaign across 17 healthcare and social care organizations in Lombardy, Italy. Approximately 45,000 eligible workers are expected to be included, covering both staff who provide patient care and those in administrative, technical, and support roles.
Workplace groups, such as departments or organizational units, are randomly assigned to one of four email communication approaches:
Researchers will use existing vaccination and employment records to compare the percentage of workers who receive a flu vaccine in each group by the end of the campaign. They will also examine whether the emails encourage earlier vaccination and whether their effects differ across workplaces and staff groups. Where suitable records are available, they will explore differences in sickness absence during the campaign.
Vaccination will remain voluntary, and all workers will continue to have access to the usual vaccination services. The study involves workplace emails and the use of existing records; no additional medical visits, tests, or procedures are required.
The findings will help healthcare organizations decide whether simple changes to routine communication can improve staff flu vaccination rates and which approach works best.
Seasonal influenza represents a major public health issue, associated with morbidity, mortality, pressure on healthcare services, workforce absenteeism and risk of transmission in care settings. Influenza vaccination of healthcare and non-healthcare workers employed in healthcare and social care organisations is an important preventive measure, not only for individual protection, but also for the indirect protection of frail patients, reduction of transmission in healthcare settings, preservation of continuity of care and resilience of healthcare services. Despite the availability of influenza vaccination and public health recommendations, vaccination uptake among healthcare and non-healthcare workers remains suboptimal and variable across organisations, professional profiles and organisational units. Communication strategies informed by behavioural science, commonly referred to as "nudges", represent low-cost, scalable organisational interventions that may guide individuals towards preventive behaviours while preserving individual autonomy. The study aims to evaluate the effectiveness of an organisational and behavioural communication strategy with potential impact on prevention, quality of care pathways, workforce resilience and public health.
Primary objective: to evaluate the effectiveness of nudge-based communication strategies, assigned at organisational cluster level, in increasing influenza vaccination uptake among eligible healthcare and non-healthcare workers during the 2026-2027 influenza vaccination campaign compared with standard institutional communication.
Secondary objectives:
Primary endpoint:
Influenza vaccination uptake during the 2026-2027 influenza vaccination campaign, defined as the proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period. Documented vaccinations will be considered irrespective of the setting in which they are administered, including vaccinations administered within the participating organisation or through other authorised vaccination pathways, where captured by ARVAX or other applicable regional administrative data sources.
Secondary endpoints:
Population and patient selection criteria: The study population consists of healthcare and non-healthcare workers eligible for influenza vaccination during the 2026-2027 campaign and belonging to organisational clusters included in the study within the 17 participating Lombardy organisations.
In this protocol, the term "patients/subjects" should be understood as "study participants/workers", since the study is not conducted on assisted patients. Inclusion criteria: employment or affiliation with one of the 17 participating organisations; belonging to an included and randomised organisational cluster; eligibility for influenza vaccination according to applicable regional/organisational recommendations; availability in administrative data flows required to define the denominator; and availability of vaccination outcome data through administrative, regional or organisational data sources.
Exclusion criteria: non-eligibility for influenza vaccination; lack of minimum data required for denominator definition, cluster attribution or outcome ascertainment; belonging to clusters that are not classifiable, mappable or randomizable; termination of employment/affiliation before the start of the campaign if not exposed to the possibility of organisational vaccination; or any other administrative condition preventing correct attribution to cluster, study arm or outcome.
Study design: This is a pragmatic, multicentre, four-arm, parallel-group, cluster-randomised, non-pharmacological procedural-organisational interventional study, prospectively implemented during the 2026-2027 influenza vaccination campaign. Randomisation will occur at the level of organisational clusters, defined as organisational units uniformly identified across participating centres according to FLUPER or another consistent organisational classification available within the participating organisations. Clusters will be allocated in a 1:1:1:1 ratio to one of four arms: standard communication, gain framing, loss framing, and social norms/peer feedback. Outcomes and denominators will be assessed using routinely available administrative, regional and organisational data flows, including FLUPER, the regional healthcare workforce administrative flow used to support workforce denominator definition and organisational classification, and ARVAX, the regional vaccination registry/database used to ascertain vaccination uptake; where available, organisational workforce or human resources data flows used to assess cluster-level sickness absence indicators will be used.
Description of the intervention: The intervention consists of institutional e-mail communications sent by the Vaccination Unit or the competent organisational function of each participating organisation, with content differentiated according to the study arm assigned to the cluster.
The comparator is standard/informational communication, corresponding to routine communication on the launch of the vaccination campaign and on access procedures.
Number of participants planned: The overall expected number of participants will be determined based on FLUPER/organisational data flows and other available administrative sources from the 17 participating organisations before final randomisation. All eligible healthcare and non-healthcare workers belonging to the randomised clusters are expected to be included.
Total number planned: approximately 45,000 healthcare and non-healthcare workers across all 17 participating organisations, subject to confirmation based on the final eligible workforce denominator derived from FLUPER and/or organisational administrative data flows before randomisation. Number planned per arm: approximately one quarter of the overall eligible population, depending on the number and size of randomised cluster
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Standard communication: standard e-mail informing that the vaccination campaing is ongoing and inviting healthcare workers to participate.
Behavioral: Control email
Gain framing: e-mail emphasising the benefits of vaccination for the worker, patients, colleagues and the organisation.
Behavioral: Gain framing email
Loss framing: e-mail emphasising the risks and potential negative consequences of non-vaccination for the worker, patients, colleagues and the organisation.
Behavioral: Loss framing email
Social norms: weekly e-mails providing updates on campaign progress and comparison between the vaccination uptake rate of the recipient's cluster and that of other clusters assigned to the same experimental arm.
Behavioral: Social norms email
Dear Colleague, The seasonal flu vaccination campaign is underway. Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications. Getting vaccinated against flu protects both individual and community health: * It reduces the spread of the flu virus, benefiting care recipients, patients, colleagues, and family members. * It reduces the risk of complications in people with chronic conditions. * It reduces the risk of a heart attack in the seven days following a confirmed flu infection. If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided. Thank you for your attention and for contributing to this prevention effort.
Dear Colleague, The seasonal flu vaccination campaign is underway. Flu is not always a mild illness. Globally, it is estimated to cause 3-5 million cases of severe illness and 290,000-650,000 deaths associated with respiratory disease each year. In Italy, more than 21,000 hospital admissions each year are attributable to flu or related respiratory and cardiovascular complications. Not getting vaccinated against flu increases both individual and community risks: * It increases the spread of the flu virus, affecting care recipients, patients, colleagues, and family members. * It increases the risk of complications in people with chronic conditions. * It increases the risk of a heart attack in the seven days following a confirmed flu infection. If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided. Thank you for your attention and for contributing to this prevention effort.
Dear Colleague, The seasonal flu vaccination campaign is underway. To encourage staff vaccination, the Agency will send a brief weekly update on the campaign's progress from now through December. These updates will compare vaccination rates across selected organizational units within the Agency. The units were selected at random and were formed by grouping organizational structures with similar areas of activity. If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided. Thank you for your attention and for contributing to this prevention effort.
Dear Colleague, The seasonal flu vaccination campaign is underway. If you have not yet been vaccinated, please remember that you can receive your vaccination by following the instructions previously provided. Thank you for your attention and for contributing to this prevention effort.
Influenza vaccination uptake at the end of 2026-2027 campaign.
Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination by the end of the observation period of the campaign.
Time frame: Up to 6 months
Influenza vaccination uptake at mid 2026-2027 campaign.
Proportion of eligible healthcare and non-healthcare workers within the randomised clusters who receive influenza vaccination at mid of the campaign.
Time frame: Up to 3 months
Change in influenza vaccination uptake between seasons.
Absolute percentage-point change in influenza vaccination uptake between the 2026-2027 campaign and the 2025-2026 campaign.
Time frame: Baseline and 6 months
Time to vaccination.
The number of days between the delivery of the communication assigned to the cluster and the documented date of influenza vaccination.
Time frame: Up to 6 months
Sickness absence.
Number of sickness absence days and/or sickness absence rates standardised by eligible population or person-time.
Time frame: Up to 6 months
Plan to share: No — No IPD data will be collected as part of the study.
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.
Of 147 non-industry interventional studies with no phase under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's planned 5 months is below that.
Counting every sponsor, half of 167 studies reached it within 6 months; a quarter within 3 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.